Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty A Multicenter Randomized Double‐Blind Placebo‐Controlled Trial

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Circulation

• Publication date

  1993-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.88.4.1588PMID 8403306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lumen narrowing after percutaneous transluminal coronary balloon angioplasty follows a near gaussian distribution: a quantitative angiographic study in 1,445 successfully dilated lesions.

  1992cited by this paper
• ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.

  1992cited by this paper
• Novel approach to the analysis of restenosis after the use of three new coronary devices.

  1992cited by this paper
• Antiproliferative effects of the serotonin type 2 receptor antagonist, ketanserin, on smooth muscle cell growth in rats.

  1991cited by this paper
• Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury.

  1991cited by this paper
• Restenosis following coronary angioplasty

  1991cited by this paper
• Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).

  1991cited by this paper
• Clinical trials of restenosis after coronary angioplasty.

  1991cited by this paper
• Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF

  1991cited by this paper
• Different interactions of platelets with arterial and venous coronary bypass vessels.

  1991cited by this paper
• Essentials of Medical Statistics

  1991cited by this paper
• Platelets and coagulation.

  1991cited by this paper
• Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients.

  1991cited by this paper
• Oral dosing with ketanserin to control high blood pressure in the elderly.

  1990cited by this paper
• Effects of chronic oral branched-chain amino acid supplementation in a subpopulation of cirrhotics.

  1990cited by this paper
• Serotonin plays a major role in serum-induced phospholipase C-mediated hydrolysis of phosphoinositides and DNA synthesis in vascular smooth muscle cells.

  1990cited by this paper
• The Role of the Endothelium in the Cardiovascular Response to Serotonin

  1990cited by this paper
• Ketanserin in Wound Healing and Fibrosis: Investigations into its Mechanism of Action

  1990cited by this paper
• 5-Hydroxytryptamine and thromboxane A2 in ischaemic heart disease.

  1990cited by this paper
• Restenosis following coronary angioplasty.

  1990cited by this paper
• Amplification Mechanisms in Platelet Activation

  1990cited by this paper
• Ketanserin prevents early restenosis following percutaneous transluminal coronary angioplasty.

  1990cited by this paper
• Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat.

  1990cited by this paper
• Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplasty.

  1989cited by this paper
• Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications

  1989cited by this paper
• Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries.

  1989cited by this paper
• Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.

  1988cited by this paper
• Incidence ofrestenosis after successful coronary angioplasty: a time-related phenomenon

  1988cited by this paper
• Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway.

  1988cited by this paper
• Coronary atherectomy light microscopic and immunohistochemical study of excised tissues

  1988cited by this paper
• Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.

  1988cited by this paper
• Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months.

  1988cited by this paper
• Platelet accumulation in experimental angioplasty: time course and relation to vascular injury.

  1987cited by this paper
• Long-acting coronary vasodilatory action of the molsidomine metabolite Sin 1: a quantitative angiographic study.

  1987cited by this paper
• Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin.

  1987cited by this paper
• Morphologic evidence of accelerated left main coronary artery stenosis: a late complication of percutaneous transluminal balloon angioplasty of the proximal left anterior descending coronary artery.

  1987cited by this paper
• Restenosis following percutaneous transluminal angioplasty: clinical, physiologic and pathological features.

  1986cited by this paper
• Stimulation of aortic smooth muscle cell mitogenesis by serotonin.

  1986cited by this paper
• Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries.

  1986cited by this paper
• Approaches towards standardization in acquisition and quantitation of arterial dimensions from cineangiograms

  1986cited by this paper
• S2-SEROTONERGIC RECEPTOR INHIBITION (KETANSERIN), COMBINED WITH THROMBOXANE A2/PROSTAGLANDIN ENDOPEROXIDE RECEPTOR BLOCKADE (BM 13177) : ENHANCED ANTI-PLATELET EFFECT

  1986cited by this paper
• Correlation of Plasma Serotonin Changes with Platelet Aggregation in an in Vivo Dog Model of Spontaneous Occlusive Coronary Thrombus Formation

  1986cited by this paper
• The pathogenesis and prevention of aortocoronary vein bypass graft occlusion and restenosis after arterial angioplasty: role of vascular injury and platelet thrombus deposition.

  1986cited by this paper
• Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty.

  1985cited by this paper
• Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.

  1985cited by this paper
• Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model.

  1985cited by this paper
• Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.

  1985cited by this paper
• Serotonin release and phosphoinositide breakdown in thrombin-induced activation of human platelets.

  1985cited by this paper
• Angiographic morphology and the pathogenesis of unstable angina pectoris.

  1985cited by this paper
• Serotonergic mechanisms in the cardiovascular system.

  1985cited by this paper
• Detection of platelet deposition at the site of peripheral balloon angioplasty using indium-111 platelet scintigraphy.

  1985cited by this paper
• Platelets, Macrophages, Endothelium, and Growth Factors Their Effects upon Cells and their Possible Roles in Atherogenesis

  1985cited by this paper
• Angiographie morphology and the pathogenesis of unstable angina pectoris

  1985cited by this paper
• The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.

  1984cited by this paper
• Percutaneous Transluminal Coronary Angioplasty: Report of Complications from the National Heart, Lung, and Blood Institute PTCA Registry

  1983cited by this paper
• Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease.

  1981cited by this paper
• Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

  1981cited by this paper
• Transluminal Angioplasty: Correlation of Morphologic and Angiographic Findings in an Experimental Model

  1980cited by this paper
• Serotonin and Ribonucleic Acid and Collagen Metabolism of Fibroblasts in Vitro 1

  1972cited by this paper
• Effects of serotonin, indomethacin and other antirheumatic drugs on the synthesis of collagen and other proteins in granulation tissue slices.

  1972cited by this paper

• Editorial: Is the axiom of balloon angioplasty, "the more you gain the more you lose", still true in the era of DCB with paclitaxel?

  2024cites this paper
• Binary to ternary drug-drug molecular adducts of the antihypertensive drug ketanserin (KTS) with advanced physicochemical properties.

  2023cites this paper
• The quest for effective pharmacological suppression of neointimal hyperplasia.

  2020cites this paper
• 3 Roles of Serotonin in Atherothrombosis and Related Diseases

  2018cites this paper
• Ovid : Ketanserin Reduces Graft Arteriosclerosis After Allogeneic Aorta Transplantation

  2015cites this paper
• Anorectic drugs and valvular heart disease: A biological and clinical perspective

  2013cites this paper
• Roles of Serotonin in Atherothrombosis and Related Diseases

  2012cites this paper
• Treatment strategies for women with coronary artery disease

  2012cites this paper
• Traditional and Novel Risk Factors in Atherothrombosis

  2012cites this paper
• 5-HT 2A Receptor: A Newer Target for Obesity

  2011cites this paper
• morpholinoethoxy ) phenyl ) benzamide ( APD 791 ) : AHighly Selective 5-Hydroxytryptamine 2 A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis

  2010cites this paper
• Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.

  2010cites this paper
• Comparative Validation of Quantitative Coronary Angiography Systems

  2009cites this paper
• Agomelatine, a melatonin agonist with antidepressant properties

  2009cites this paper
• Disrupted Serotonergic and Sympathoadrenal Systems in Patients with Chronic Heart Failure May Serve as New Therapeutic Targets and Novel Biomarkers to Assess Severity, Progression and Response to Treatment

  2009cites this paper
• Irradiation and dosimetry of Nitinol stent for renal artery brachytherapy.

  2009cites this paper
• Practice Guidelines (8th Edition) of Chest Physicians Evidence-Based Clinical Coronary Artery Disease: American College The Primary and Secondary Prevention of

  2008cites this paper
• The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.

  2006cites this paper
• Therapeutic potentials of sarpogrelate in cardiovascular disease.

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)

  2006cites this paper
• XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China.

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cites this paper
• Impact of frame selection on quantitative coronary angiographic analysis after coronary stenting

  2005cites this paper
• The drug-based pipeline against restenosis

  2005cites this paper
• Citing Articles via Google Scholar

  2004cites this paper
• Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• The potential role of homocysteine in percutaneous coronary interventions (PCI): review of current evidence and plausibility of action.

  2004cites this paper
• Sarpogrelate: cardiovascular and renal clinical potential

  2004cites this paper
• The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation

  2003cites this paper
• Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation.

  2003cites this paper
• Treating atherosclerosis: local drug delivery from laboratory studies to clinical trials.

  2002cites this paper
• Histomorphometric evaluation of (198)Au endovascular brachytherapy in a renal artery restenosis model in rabbits.

  2002cites this paper
• Comparison of two different methods of quantitative coronary angiography in patients with acute coronary syndromes

  2002cites this paper
• Can Angiotensin Receptor Antagonists Prevent Restenosis After Stent Placement?

  2002cites this paper
• Overview of therapies for prevention of restenosis after coronary interventions.

  2001cites this paper
• The Restenosis Story: Is Intracoronary Radiation Therapy the Solution?

  2001cites this paper
• Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era.

  2001cites this paper
• Intracoronary radiation therapy.

  2001cites this paper
• Advances in Interventional Cardiology II: A Case Study

  2001cites this paper
• Antithrombotic therapy in patients undergoing percutaneous coronary intervention.

  2001cites this paper
• Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty

  2000cites this paper
• Farmakologiczne próby zapobiegania restenozie

  2000cites this paper
• Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. Dose Finding Study Group.

  2000cites this paper
• Measurement of radiation absorbed dose in endovascular Ho-166 brachytherapy using a balloon angio-catheter

  2000cites this paper
• Chronic Rejection in the Aorta Transplantation Model

  1999cites this paper
• Synergy between thrombin and serotonin in inducing vascular smooth muscle cell proliferation.

  1999cites this paper
• Coronary atherosclerosis and interventions: Pathological sequences and restenosis

  1999cites this paper
• Gbetagamma‐Mediated Signaling: New Therapeutic Target for Proliferative Vascular Disease

  1999cites this paper
• Thrombus organization plays no major role in late neointimal formation after angioplasty in porcine coronary arteries.

  1999cites this paper
• Testosteron bei Patienten mit koronarer Herzkrankheit - ein angiograpisches Langzeit-Follow-up

  1999cites this paper
• Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty

  1999cites this paper
• G¯°-Mediated Signaling: New Therapeutic Target for Proliferative Vascular Disease

  1999cites this paper
• Serotonin is associated with coronary artery disease and cardiac events.

  1999cites this paper
• A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.

  1999cites this paper
• Medical therapies for the prevention of restenosis after percutaneous coronary interventions.

  1998cites this paper
• From cell culture to population enquiry: Experimental, clinical and epidemiological studies on restenosis post coronary intervention

  1998cites this paper
• Restenosis, the Achilles' Heel of Coronary Angioplasty

  1998cites this paper
• [Mechanisms and prevention of restenosis after coronary angioplasty].

  1998cites this paper
• β3 Integrins Are Upregulated After Vascular Injury and Modulate Thrombospondin- and Thrombin-Induced Proliferation of Cultured Smooth Muscle Cells

  1998cites this paper
• Morphometric and Histologic Assessment of Remodeling Associated with Restenosis after Percutaneous Transluminal Coronary Angioplasty

  1998cites this paper
• Endovascular manipulation to restrict restenosis

  1998cites this paper
• Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells.

  1998cites this paper
• Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty

  1998cites this paper
• Anorectic drugs and valvular heart disease: a biological and clinical perspective.

  1998cites this paper
• Antithrombotic therapy in patients undergoing coronary angioplasty.

  1998cites this paper
• Pharmacological treatments for restenosis

  1997cites this paper
• Safety of low dose heparin in elective coronary angioplasty.

  1997cites this paper
• Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization

  1997cites this paper
• Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit.

  1997cites this paper
• Restenosis after coronary angioplasty.

  1997cites this paper
• Care of the Patient and Management of Complications after Percutaneous Coronary Artery Interventions

  1997cites this paper
• Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

  1997cites this paper
• New antiplatelet drugs.

  1997cites this paper
• Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures.

  1997cites this paper
• Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation.

  1997cites this paper
• Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

  1997cites this paper
• Use of Glycoprotein lib/ilia Inhibitors in Acute Coronary Syndromes

  1997cites this paper
• The pathobiology of restenosis after percutaneous revascularisation: Current concepts and therapeutic objectives

  1997cites this paper
• Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement

  1997cites this paper
• Clinical use of intravenous glycoprotein IIb/IIIa inhibitors

  1997cites this paper
• Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention

  1997cites this paper
• Expert Answers to Three Key Questions

  1997cites this paper
• Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.

  1997cites this paper
• Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study)

  1996cites this paper
• Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis.

  1996cites this paper
• Angiographic assessment of immediate success and the problem (definition) of restenosis after coronary interventions

  1996cites this paper
• Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease.

  1996cites this paper
• Contributions of frequency distribution analysis to the understanding of coronary restenosis. A reappraisal of the gaussian curve.

  1996cites this paper
• Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures.

  1996cites this paper
• Ketanserin reduces graft arteriosclerosis after allogeneic aorta transplantation in rats.

  1996cites this paper
• The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease.

  1996cites this paper
• Short- and long-term clinical and quantitative angiographic results with the new, less shortening Wallstent for vessel reconstruction in chronic total occlusion: a quantitative angiographic study.

  1996cites this paper
• Management of restenosis after coronary intervention.

  1996cites this paper
• Uncoupling clinical outcomes and coronary angiography: a review and perspective of recent trials in coronary artery disease.

  1996cites this paper
• Intracoronary irradiation: dose response for the prevention of restenosis in swine.

  1996cites this paper
• Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis.

  1995cites this paper
• Comparative validation of quantitative coronary angiography systems. Results and implications from a multicenter study using a standardized approach.

  1995cites this paper
• Alterations in reference vessel diameter following intracoronary stent implantation: important consequences for restenosis based on percent diameter stenosis.

  1995cites this paper